Risk and prognosis of endometrial cancer after tamoxifen for breast cancer
The LancetPublished 1 September 2000
Liesbeth Bergman, Maureen LR Beelen, M.P.W. Gallee, Harry Hollema, J. Benraadt, Flora E. van Leeuwen
Citations546
SJR quartileQ1
SJR score12.11
SNIP22.72
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Long-term tamoxifen users have a worse prognosis of endometrial cancers, which seems to be due to less favourable histology and higher stage, however, the benefit of tamoxIFen on breast-cancer survival far outweighs the increased mortality from endometricrial cancer.
Abstract
Long-term tamoxifen users have a worse prognosis of endometrial cancers, which seems to be due to less favourable histology and higher stage. However, the benefit of tamoxifen on breast-cancer survival far outweighs the increased mortality from endometrial cancer. Nevertheless, we seriously question widespread use of tamoxifen as a preventive agent against breast cancer in healthy women.
Keywords
MedicineBiochemistry, Genetics and Molecular Biology
Cancer Incidence in Five Continents
8,539 Citations1970Richard Doll, C. S. Muir +1 more
JNCI Journal of the National Cancer InstituteTamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
5,508 Citations1998Bernard Fisher, Joseph P. Costantino +15 more
Tamoxifen decreases the incidence of invasive and noninvasive breast cancer and its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.
The LancetTamoxifen for early breast cancer: an overview of the randomised trials
4,105 Citations1998Early Breast Cancer Tr.group, -, Klijn, Jan
The absolute improvement in recurrence was greater during the first 5 years, whereas the improvement in survival grew steadily larger throughout the first 10 years, and these benefits appeared to be largely irrespective of age, menopausal status, daily tamoxifen dose, and of whether chemotherapy had been given to both groups.
PubMedPolychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
2,156 Citations1998C. Focan, S. M. Steinberg +225 more
JNCI Journal of the National Cancer InstituteEndometrial Cancer in Tamoxifen-Treated Breast Cancer Patients: Findings From the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 *
1,280 Citations1994B. Fisher, Joseph P. Costantino +5 more
Risk of endometrial cancer increases following tamoxifen therapy for invasive breast cancer; however, net benefit greatly outweighs risk, and tamoxIFen treatment for breast cancer should continue.
The LancetADJUVANT TAMOXIFEN IN EARLY BREAST CANCER: OCCURRENCE OF NEW PRIMARY CANCERS
930 Citations1989Tommy� Fornander, Björn Cedermark +10 more
The frequency of new primary cancers was studied in 1846 postmenopausal patients included in a randomised trial of tamoxifen as an adjunct to primary surgery for early breast cancer and the increase in endometrial cancers was most pronounced in those treated for over 2 years.
The LancetInterim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
886 Citations1998Trevor J. Powles, Rosalind A. Eeles +7 more
The authors have been unable to show any effect of tamoxifen on breast-cancer incidence in healthy women, contrary to the report from the NSABP-P1 study showing a 45% reduction inhealthy women given tamoxIFen versus placebo.
The LancetPrevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women
770 Citations1998Umberto Veronesi, Patrick Maisonneuve +6 more
In this cohort of women at low-to-normal risk of breast cancer, the postulated protective effects of tamoxifen are not yet apparent and it is essential to continue follow-up to quantify the long-term risks and benefits of tamxifen therapy.
The LancetRisk of endometrial cancer after tamoxifen treatment of breast cancer
571 Citations1994Flora E. van Leeuwen, Alexandra W. van den Belt‐Dusebout +12 more
The hypothesis that tamoxifen use increases the risk of endometrial cancer is supported, as the oestrogenic effect on the endometrium was not related to the dose intensity.
JNCI Journal of the National Cancer InstituteAdjuvant Tamoxifen Therapy for Early Stage Breast Cancer and Second Primary Malignancies
509 Citations1995Lars Erik Rutqvist, Hemming Johansson +4 more
The endometrium and gastrointestinal organs may be target sites for tamoxifen-induced carcinogenesis in humans and the increased incidence of colorectal and stomach cancers reported here should be regarded as tentative until supported by long-term data from a larger number of tamoxIFen trials.
Histological Typing of Female Genital Tract Tumours
493 Citations1994Robert E. Scully, T. A. Bonfiglio +3 more
The LancetEVALUATION OF SCREENING FOR BREAST CANCER IN A NON-RANDOMISED STUDY (THE DOM PROJECT) BY MEANS OF A CASE-CONTROL STUDY
377 Citations1984H.J.A. Collette, Jan J. Rombach +2 more
In 1974 a non-randomised study of the effect of mass screening by physical examination and xeromammography on mortality from breast cancer was started, and of the 20 555 eligible women in the city of Utrecht born between 1911 and 1925, 14 796 attended for screening.
JNCI Journal of the National Cancer InstituteTamoxifen Therapy for Breast Cancer and Endometrial Cancer Risk
363 Citations1999Leslie Bernstein, Dennis Deapen +6 more
ERT use and obesity, both established endometrial cancer risk factors and markers of estrogen exposure, substantially modify the association between tamoxifen use and endometrian cancer risk among patients with breast cancer.
Journal of Clinical OncologyHigh-grade endometrial carcinoma in tamoxifen-treated breast cancer patients.
354 Citations1993Urania Magriples, Frederick Naftolin +2 more
Women receiving tamoxifen as treatment for breast cancer who subsequently develop uterine cancer are at risk for high-grade endometrial cancers that have a poor prognosis, and findings indicate that tamoxIFen-associated uterine cancers may have a different basis from those associated with steroidal estrogen treatment.
Journal of Clinical PathologyPathology of endometrium treated with tamoxifen.
198 Citations1994S M Ismail
Findings support a link between prolonged tamoxifen treatment and endometrial malignancy and identify a subgroup of patients, those who have taken more than 35 g of tamoxIFen, who may be at increased risk ofendometrial cancer.
JNCI Journal of the National Cancer InstituteIncidence of New Primary Cancers After Adjuvant Tamoxifen Therapy and Radiotherapy for Early Breast Cancer
172 Citations1991Michael Andersson, Hans H. Storm +1 more
The incidence of new primary cancers was evaluated in 3538 postmenopausal patients who had received surgical treatment for primary breast cancer and a tendency to an elevated risk of endometrial cancer was observed.
Gynecologic OncologyTamoxifen Use in Breast Cancer Patients Who Subsequently Develop Corpus Cancer Is Not Associated with a Higher Incidence of Adverse Histologic Features
162 Citations1994Richard R. Barakat, George Wong +3 more
A retrospective review of corpus cancers developing in breast cancer patients demonstrated no significant difference in stage, grade, or histologic subtype based on tamoxifen use.
JNCI Journal of the National Cancer InstitutePopulation-Based Study of Tamoxifen Therapy and Subsequent Ovarian, Endometrial, and Breast Cancers
145 Citations1995Linda S. Cook, Noel S. Weiss +5 more
It is suggested that short durations of tamoxifen therapy are not associated with an increased risk of endometrial or ovarian cancer but are associated with a reduction in contralateral breast cancer risk.
PubMedLack of genotoxicity of tamoxifen in human endometrium.
128 Citations1996Paul L. Carmichael, Austin Ugwumadu +4 more
Examination of the explant culture media from endometria treated with tamoxifen revealed the presence of the alpha-hydroxy metabolite in a dose-dependent manner, although apparently at levels insufficient to produce detectable DNA adducts.
International Journal of CancerIatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study
101 Citations1998H. Mignotte, Christine Lasset +18 more
A causal role of tamoxifen in endometrial cancer is suggested, particularly when used as currently proposed for breast cancer prevention, and a long‐term evaluation of the risk–benefit ratio of tamxifen as a preventive treatment for Breast cancer is clearly warranted.
Archiv für Pathologische Anatomie und Physiologie und für Klinische MedicinImmunohistochemical analysis of p53 protein over-expression in endometrial carcinomas: Inverse correlation with sex steroid receptor status
54 Citations1993Masafumi Koshiyama, Ikuo Konishi +7 more
Clinopathological features of p53-positive carcinomas and the inverse correlation of p 53 immunoreactivity with sex steroid receptor status suggest that p53 over-expression is frequent in a specific category of endometrial carcinoma, presumably oestrogen-unrelated tumours.
EpidemiologyEndometrial Cancer following Breast Cancer
54 Citations1996Annie J. Sasco, Gilles Chaplain +2 more
A case-control study in Lyon and Dijon, France, to assess the effect of tamoxifen and other treatments for breast cancer on subsequent endometrial cancer.
Gynecologic OncologyUterine mullerian adenosarcoma following adenomyoma in a woman on tamoxifen therapy
51 Citations1992Thèrése Bocklage, Kenneth R. Lee +1 more
The possible stimulatory effects of this drug upon the patient's pre-existing adenomyoma are discussed in view of reports of tamoxifen-associated endometrial carcinoma and uterine sarcomas developing in the setting of estrogen excess.
Gynecologic OncologyRole of Prolonged Stimulation of Tamoxifen Therapy in the Etiology of Endometrial Sarcomas
50 Citations1993Marco M. Altaras, Rami Aviram +4 more
The first case of heterologous mixed mesodermal tumor that developed 9 years following tamoxifen therapy in a climacteric woman with no previous pelvic irradiation and was initially treated by total abdominal hysterectomy and bilateral salpingo-oophorectomy is presented.
International Journal of Gynecological PathologyMucinous and Clear Cell Adenocarcinomas of the Endometrium in Patients Receiving Antiestrogens (Tamoxifen) and Gestagens
49 Citations1995Gisela Dallenbach-Hellweg, Uwe Hahn
It is believed that gestagen therapy administered to patients with endometrioid type carcinoma is contraindicated in patients with mucinous adenocarcinoma of the endometrium and that this is another reason to distinguish between these two types of carcinoma.
Journal of Clinical PathologyThe hormonal receptor status of uterine carcinosarcomas (mixed müllerian tumours): an immunohistochemical study.
32 Citations1997Anca C. Ansink, Paul Cross +3 more
Receptors for oestrogen and progesterone hormone receptors were found in four of 11 cases of uterine carcinosarcoma, using paraffin embedded material, and there may be an association between hormone receptor positivity and clinical outcome.
International Journal of Gynecology & ObstetricsEstrogen receptor content, immunohistochemically determined by monoclonal antibodies, in endometrial stromal sarcoma
25 Citations1989P Tosi, Vincenzo Sforza +1 more
The presence of positive immunostaining to vimentin confirms the mesenchymal origin of endometrial stromal sarcoma, and it is postulated that estrogen receptors are undetectable only in highly proliferating neoplasms.
International Journal of Gynecology & ObstetricsEndometrial müllerian carcinosarcoma after cessation of tamoxifen therapy for breast cancer
21 Citations1995Annie J. Sasco, F Raffi +4 more
A case of heterologous mixed malignant müllerian tumor occurring in an 80‐year‐old woman who had been diagnosed with breast cancer and received tamoxifen for a total of 55 months over a 6‐year period is reported.
International Journal of Gynecological PathologyRandom Nuclear p53 Overexpression Pattern In Tamoxifen-Mediated Endometrial Carcinoma
12 Citations1998Y Kuwashima, Masafumi Kurosumi +7 more
P53 overexpression in endometrial carcinomas occurring in patients with breast cancer seems to be not specific for TAM-treated patients, and, if DNA adduct formation has any role in this type of endometrian carcinogenesis, it may not be related preferentially to p53 gene alteration.
European Journal of CancerIV.6 Tamoxifen and endometrial cancer: most cancers are early stage and highly curable
10 Citations1998R. Barakat
A large randomised trial comparing tamoxifen with placebo for breast cancer treatment has demonstrated an average annual hazard rate for endometrial cancer in the placebo group of 0.2 1000 compared to 1.6 1000 for the tamxifen-treated group, with tamoxIFen causing a 7.5-fold increase in the relative risk of endometrian cancer.
PubMedA case-case analysis of factors related to overexpression of p53 in endometrial cancer following breast cancer.
7 Citations1997Sara H. Olson, Connie L. Finstad +4 more
Genetic predisposition to cancer, as reflected in family history of breast cancer and personal history of an additional primary cancer, was strongly associated with overexpression of p53 in endometrial tumors, and use of tamoxifen may be associated with an increase in tumors that overexpress p53.
European Journal of CancerIV.2 Does risk of endometrial cancer increase with longer duration of tamoxifen use?
5 Citations1998Flora E. van Leeuwen, Liesbeth Bergman +1 more
The effects of tamoxifen duration and dosage on the risk of endometrial cancer have not yet been examined extensively and in the six studies that examined the effect of duration of treatment, a significantly positive trend was found in four, a non-significant positive trend in one and a non -significant negative trend in two.
European Journal of CancerII.6 Alterations in steroid hormone receptors in the tamoxifen-treated endometrium
3 Citations1998Lisa Barrie Schwartz
The tamoxifen-associated changes in endometrial steroid receptors support an estrogenic effect that is independent of histologic diagnosis and duration of use, which may contribute to the pathogenesis of tamoxIFen- associated polyps and carcinomas.